Clinical Trial Update: Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib in metastatic thyroid cancer patients non-responsive to radioactive iodine; study completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Cancer
• Insular Thyroid Cancer
• Papillary Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Insular Thyroid Cancer, Recurrent Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-06-25